Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Insulin Resistance, Diabetes, and Cardiovascular Risk

(2014) Francesco Paneni et al.   Current Atherosclerosis Reports

Liraglutide Enhances Insulin Sensitivity by Activating AMP-Activated Protein Kinase in Male Wistar Rats

(2014) Satoru Yamazaki et al.   ENDOCRINOLOGY

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

(2014) Nadia M. Krasner et al.   PLoS One

Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice

(2013) LI-NA CHEN et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

(2013) Yutaka Seino et al.   Journal of Diabetes Investigation

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

(2012) Aya Shiraki et al.   ATHEROSCLEROSIS

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

(2012) Mohammad Hossein Noyan-Ashraf et al.   CIRCULATION

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

(2011) Kana Inoue et al.   Cardiovascular Diabetology

Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

(2011) B. Vergès et al.   DIABETES & METABOLISM

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

(2011) Tracey Gaspari et al.   Diabetes & Vascular Disease Research

Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects

(2011) J. Joya-Galeana et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

(2009) S. Del Prato   DIABETIC MEDICINE

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology